104 related articles for article (PubMed ID: 29254594)
1. A radiobiological Markov simulation tool for aiding decision making in proton therapy referral.
Austin AM; Douglass MJJ; Nguyen GT; Penfold SN
Phys Med; 2017 Dec; 44():72-82. PubMed ID: 29254594
[TBL] [Abstract][Full Text] [Related]
2. Patient selection for proton therapy: a radiobiological fuzzy Markov model incorporating robust plan analysis.
Austin AM; Douglass MJJ; Nguyen GT; Penfold SN
Phys Eng Sci Med; 2020 Jun; 43(2):493-503. PubMed ID: 32524433
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of proton therapy in treating base of skull chordoma.
Austin AM; Douglass MJJ; Nguyen GT; Dalfsen R; Le H; Gorayski P; Tee H; Penniment M; Penfold SN
Australas Phys Eng Sci Med; 2019 Dec; 42(4):1091-1098. PubMed ID: 31646441
[TBL] [Abstract][Full Text] [Related]
4. Proton therapy for base of skull chordoma: a report for the Royal College of Radiologists. The Proton Therapy Working Party.
Clin Oncol (R Coll Radiol); 2000; 12(2):75-9. PubMed ID: 10853743
[TBL] [Abstract][Full Text] [Related]
5. Spot scanning proton therapy for malignancies of the base of skull: treatment planning, acute toxicities, and preliminary clinical outcomes.
Grosshans DR; Zhu XR; Melancon A; Allen PK; Poenisch F; Palmer M; McAleer MF; McGovern SL; Gillin M; DeMonte F; Chang EL; Brown PD; Mahajan A
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):540-6. PubMed ID: 25304948
[TBL] [Abstract][Full Text] [Related]
6. Impact of spot size on plan quality of spot scanning proton radiosurgery for peripheral brain lesions.
Wang D; Dirksen B; Hyer DE; Buatti JM; Sheybani A; Dinges E; Felderman N; TenNapel M; Bayouth JE; Flynn RT
Med Phys; 2014 Dec; 41(12):121705. PubMed ID: 25471952
[TBL] [Abstract][Full Text] [Related]
7. Monte Carlo role in radiobiological modelling of radiotherapy outcomes.
El Naqa I; Pater P; Seuntjens J
Phys Med Biol; 2012 Jun; 57(11):R75-97. PubMed ID: 22571871
[TBL] [Abstract][Full Text] [Related]
8. Referring patients abroad for proton therapy.
Wilson E
Clin Oncol (R Coll Radiol); 2000; 12(2):71-2. PubMed ID: 10853741
[No Abstract] [Full Text] [Related]
9. Obtaining funding for proton therapy at Orsay, France.
Taylor RE
Clin Oncol (R Coll Radiol); 2000; 12(2):73-4. PubMed ID: 10853742
[No Abstract] [Full Text] [Related]
10. Technical note: Optimal allocation of limited proton therapy resources using model-based patient selection.
Papp D; Unkelbach J
Med Phys; 2022 Aug; 49(8):4980-4987. PubMed ID: 35715935
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of proton beam therapy for intraocular melanoma.
Moriarty JP; Borah BJ; Foote RL; Pulido JS; Shah ND
PLoS One; 2015; 10(5):e0127814. PubMed ID: 25993284
[TBL] [Abstract][Full Text] [Related]
12. Assessing the uncertainty in a normal tissue complication probability difference (∆NTCP): radiation-induced liver disease (RILD) in liver tumour patients treated with proton vs X-ray therapy.
Kobashi K; Prayongrat A; Kimoto T; Toramatsu C; Dekura Y; Katoh N; Shimizu S; Ito YM; Shirato H
J Radiat Res; 2018 Mar; 59(suppl_1):i50-i57. PubMed ID: 29538699
[TBL] [Abstract][Full Text] [Related]
13. Treatment plan comparison between helical tomotherapy and MLC-based IMRT using radiobiological measures.
Mavroidis P; Ferreira BC; Shi C; Lind BK; Papanikolaou N
Phys Med Biol; 2007 Jul; 52(13):3817-36. PubMed ID: 17664579
[TBL] [Abstract][Full Text] [Related]
14. Protons in head-and-neck cancer: bridging the gap of evidence.
Ramaekers BL; Grutters JP; Pijls-Johannesma M; Lambin P; Joore MA; Langendijk JA
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1282-8. PubMed ID: 23273998
[TBL] [Abstract][Full Text] [Related]
15. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
16. Mathematical Modelling for Patient Selection in Proton Therapy.
Mee T; Kirkby NF; Kirkby KJ
Clin Oncol (R Coll Radiol); 2018 May; 30(5):299-306. PubMed ID: 29452724
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy versus surgery for medically operable Stage I non-small-cell lung cancer: a Markov model-based decision analysis.
Louie AV; Rodrigues G; Hannouf M; Zaric GS; Palma DA; Cao JQ; Yaremko BP; Malthaner R; Mocanu JD
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):964-73. PubMed ID: 20932688
[TBL] [Abstract][Full Text] [Related]
18. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?
Konski A; Speier W; Hanlon A; Beck JR; Pollack A
J Clin Oncol; 2007 Aug; 25(24):3603-8. PubMed ID: 17704408
[TBL] [Abstract][Full Text] [Related]
19. On the new metrics for IMRT QA verification.
Garcia-Romero A; Hernandez-Vitoria A; Millan-Cebrian E; Alba-Escorihuela V; Serrano-Zabaleta S; Ortega-Pardina P
Med Phys; 2016 Nov; 43(11):6058. PubMed ID: 27806610
[TBL] [Abstract][Full Text] [Related]
20. Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease.
Ng AK; Weeks JC; Mauch PM; Kuntz KM
J Clin Oncol; 1999 Nov; 17(11):3577-85. PubMed ID: 10550157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
